Pharma Two B Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.pharma2b.com
Clinical Trials
4
Active:2
Completed:2
Trial Phases
3 Phases
Phase 1:2
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
1 (25.0%)Phase 3
1 (25.0%)A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
Phase 3
Completed
- Conditions
- Parkinson DiseaseEarly Parkinson's Disease
- Interventions
- Drug: P2B001 0.6/0.75 mg
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Pharma Two B Ltd.
- Target Recruit Count
- 544
- Registration Number
- NCT03329508
- Locations
- 🇺🇸
P2B001/003 Site Scottsdale, Scottsdale, Arizona, United States
🇺🇸P2B001/003 study site Scottsdale, Scottsdale, Arizona, United States
🇺🇸P2B001/003 Study site little Rock, Little Rock, Arkansas, United States
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),Drug: Placebo
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Pharma Two B Ltd.
- Target Recruit Count
- 149
- Registration Number
- NCT01968460
- Locations
- 🇺🇸
P2B001 Site Birmingham, Birmingham, Alabama, United States
🇺🇸P2B001 Site Los Angeles, Los Angeles, California, United States
🇺🇸P2B001 Site Aurora, Aurora, Colorado, United States
News
No news found